Broadly neutralizing antibodies (bnAbs) targeting the human immunodeficiency virus-1 (HIV-1) have played a crucial role in elucidating and characterizing neutralization-sensitive sites on the HIV-1 envelope spike and in informing vaccine development. Continual advancements in identifying more potent bnAbs, along with their capacity to trigger antibody-mediated effector functions, coupled with modifications to extend their half-life, position them as promising candidates for both HIV-1 treatment and prevention. While current pharmacological interventions have made significant progress in managing HIV-1 infection and enhancing quality of life, no definitive cure or vaccines have been developed thus far. Standard treatments involve daily oral anti-retroviral therapy, which, despite its efficacy, can lead to notable long-term side effects. Recent clinical trial data have demonstrated encouraging therapeutic and preventive potential for bnAb therapies in both HIV-1-infected individuals and those without the infection. This review provides an overview of the advancements in HIV-1-specific bnAbs and discusses the insights gathered from recent clinical trials regarding their application in treating and preventing HIV-1 infection.
Keyphrases
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- hiv positive
- clinical trial
- hiv aids
- hepatitis c virus
- hiv testing
- men who have sex with men
- radiation therapy
- dengue virus
- randomized controlled trial
- risk assessment
- physical activity
- stem cells
- drug delivery
- bone marrow
- squamous cell carcinoma
- phase ii
- cancer therapy
- south africa
- zika virus
- mesenchymal stem cells
- cell therapy